Background Vortioxetine is a novel multimodal compound that has recently been approved by the FDA for the treatment of major depressive disorder (MDD). It is a selective serotonin (5-HT ...
to the US FDA for the investigational agent vortioxetine. Vortioxetine (Lu AA21004) is under investigation as an antidepressant for the treatment of major depressive disorder (MDD) in adult patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback